The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Slides:

Advertisements

Similar presentations

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Advertisements

Goede V et al. Proc ASCO 2013;Abstract 7004.

Robertson JFR et al. J Clin Oncol 2009;27(27):

Palumbo A et al. Proc ASH 2012;Abstract 446.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Drug Treatment of Metastatic Breast Cancer

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)

New Evidence reports on presentations given at ASCO 2012

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

First-Line TKI Use in EGFR Mutation-Positive NSCLC

EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.

NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)

Follicular & Aggressive B-Cell Lymphomas. Five-year TTF and Response Duration (RD) According to FLIPI Risk Group R-CHOPCHOPP value TTF Low-risk

What are the main benefits of BRAF inhibitors in metastatic melanoma?

Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

Rituximab efficacy in other haematological malignancies Christian Buske.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,

Ruan J et al. Proc ASH 2013;Abstract 247.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Increased Incidence of Therapy- Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) vs Fludarabine (F):

1 Flinn I et al. Proc ICML 2013;Abstract 084.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Final results of phase II, randomized, double-blind study of sorafenib plus doxorubicin and placebo plus doxorubicin in patients with advanced hepatocellular.

Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.

What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Phase III Study of First-Line XELOX Plus Bevacizumab (BEV) for 6 Cycles Followed by XELOX Plus BEV or Single Agent (s/a) BEV as Maintenance Therapy in.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

ENDOMETRIAL CARCINOMA UPDATES Dr Marco Matos Gold Coast Cancer Care, Gold Coast University Hospital and Pacific Private Oncology Group.

Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

CCO Independent Conference Highlights

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL

Attal M et al. Proc ASCO 2010;Abstract 8018.

Barrios C et al. SABCS 2009;Abstract 46.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Badoux X et al. Proc ASCO 2010;Abstract 6508.

Vesole DH et al. Proc ASH 2010;Abstract 308.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Optimizing therapy for nodal marginal zone lymphoma

Presentation transcript:

The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) May 30-June 3, 2008 Chicago, Illinois

MCL confirmed locally Relapsed/refractory to 2-7 prior therapies Required: Rituximab Anthracycline Alkylating agent RANDOMIZATIONRANDOMIZATION Temsirolimus 175 mg q3w then 75 mg qw Temsirolimus 175 mg q3w then 25 mg qw Investigator’s choice single agent * Temsirolimus treatment to continue until progression, death or unacceptable toxicity Adapted from Hess et al. ASCO 2008, abstract Study Design * Protocol specified (n): Gemcitabine i.v. (22), fludarabine i.v., oral (14), chlorambucil oral (3), cladribine i.v. (3), etoposide i.v. (3), cyclophosphamide oral (2) * Approved additions (n): Thalidomide oral (2), vinblastine i.v. (2) alemtuzumab i.v. (1), lenalidomide oral (1)

PeriodTemsirolimus 175/75 n=54 Temsirolimus 175/25 n=54 Week 1-3 Mean dose intensity, mg/wk Mean relative dose intensity Week 4 – end of treatment Mean dose intensity, mg/wk Mean relative dose intensity Overall exposure Mean total exposure, mg Mean dose intensity, mg/wk Mean relative dose intensity Dose Administration and Exposure Adapted from Hess et al. ASCO 2008, abstract 8513.

Temsirolimus 175/75 n=54 Temsirolimus 175/25 n=45 Investigator’s choice n=50 Median PFS, months % CI P value vs. IC Hazard ratio 95% CI Date of data cutoff: 19 July 2007 (independent assessment) Progression-free Survival (ITT) Excluding Patients with Blastoid Histology Adapted from Hess et al. ASCO 2008, abstract 8513.